Hao, Z., Chiappori, A., Creelan, B. C., Munker, R., Schwarzenberger, P. O., Patel, N., Vahora, S., Davis, C., Wang, C., Zhang, J., Xin, L., Schoenfeld, A. J., Sands, J. (2026). Preliminary results from an ongoing phase 1 study of LB2102, a dnTGFBR2-armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNEC.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8012